Lupin Limited has introduced Azilsartan Medoxomil Tablets (40 mg and 80 mg) in the United States following approval from the U.S. Food and Drug Administration (FDA). The company launched the product as a generic equivalent of Edarbi®, expanding its cardiovascular portfolio in the U.S. market.
Regulatory Approval and Product Positioning
The launch follows Lupin’s Abbreviated New Drug Application (ANDA) approval from the FDA. The tablets are bioequivalent to the reference product and are indicated for the treatment of hypertension in adults to help lower blood pressure.
In addition, Lupin holds a competitive position in the U.S. generics market, and this launch further strengthens its presence in cardiovascular therapies.
Key Market Details
Azilsartan Medoxomil Tablets address a prescription segment used for managing high blood pressure. The product enters a market with established demand, as the reference drug Edarbi® continues to generate significant annual sales in the U.S.
Strategic Significance
The launch also reinforces Lupin’s ongoing focus on expanding its generic portfolio across key regulated markets. Moreover, the company continues to strengthen its manufacturing and regulatory capabilities to support such product introductions.
As per Lupin’s News Release
As per the Lupin news release, the company highlighted that the product launch follows FDA approval of its ANDA and that the tablets are bioequivalent to Edarbi® (Azurity Pharmaceuticals Inc.), reinforcing Lupin’s commitment to delivering affordable generic treatment options in the U.S. market.
Conclusion
Overall, this launch marks another step in Lupin’s strategy to expand its U.S. generics portfolio, particularly in the cardiovascular segment, while increasing access to cost-effective hypertension therapies.